

Confidential Briefing 6th Community Pharmacy Agreement

Paul Sinclair

President – Community Pharmacy Section, FIP President – Pharmacy Guild of Australia (NSW)

October, 2015



6th Community Pharmacy Agreement

Overview - October, 2015



Executive Summary

- Minister and Guild have signed 6CPA
 - * 5-year agreement

- * Estimated \$18.9b compared with \$15.7b in 5CPA
- Additional \$2.3b on forward estimates
- * Extension of Location Rules to mid-2020
- Dispensary remuneration maintained in real terms
- Up to \$1.26b in program funding



Dispensing Remuneration

From 1 July 2015:

- Minimum \$3.49 Administration, Handling & Infrastructure (AHI) Fee replaces mark-up
- Dispensing fee up \$0.17 to \$6.93
- Premium-free Dispensing Incentive up \$0.04 to \$1.72
- Dangerous Drug Fee up by 20 cents to \$2.91

All fees indexed annually by Consumer Price Index



Administration, Handling & Infrastructure (AHI) Fee

The AHI Fee will be:

COMMERCIAL IN

- <u>\$3.49</u> for all drugs priced up to \$180 (more than 98 percent of scripts)
- <u>\$3.49 + 3.5 percent</u> of the amount over \$180 for drugs \$180 to \$2,089.71
- Capped at \$70 at a price of \$2,089.71 and above


Benefits:

- · Delinks official remuneration from cost of medicines
- Indexed by CPI every year

COMMERCIAL IN

Puts a floor on remuneration - \$6.93 dispensing fee + \$3,49 AHI





Remuneration – Other Issues

- Review: remuneration review to inform 7CPA
- Under Co-Payment Prescriptions:
 - ★ Allowable fees continue to apply (optional)
 - * AHI also applies

- * Pricing data supplied to Medicare through PBS Online
- Wholesalers: CSP remuneration issue
- Chemotherapy: changes to fee structure proposed, to be discussed with sector, funded outside the 6CPA envelope



Location Rules

- Legislation to extend Location Rules from 1 July 2015 to 30 June 2020
- Review of Location Rules within first two years of 6CPA
- No changes during 6CPA without agreement of Guild



COMMERCIAL IN

Community Pharmacy Programs

\$1.26 billion:

- Continuing community pharmacy programs (\$613 million)
- Pharmacy trial program (\$50 million)
- Funding to support new and expanded programs (\$600 million)
- Focus on ATSI people and rural and remote Australia



Community Pharmacy Programs

Additional community pharmacy program funding:

- \$650 million to support trials and new and expanded programs delivered through community pharmacy (ex unapproved pharmacies)
- Enhancing primary healthcare role of community pharmacy
- \$122 million earmarked to expand DAAs and Staged Supply



Conclusion

COMMERCIAL IN

Significant benefits for community pharmacies:

- \$2.4 billion additional investment (\$2.8 billion including chemo)
- Dispensing (AHI provides floor, CPI indexation, 1 July increase, higher dispense remuneration every year, PFDI value retained)
- Location Rules retained to mid-2020
- 70 percent increase in community pharmacy program funding
- Opportunity to significantly enhance role of pharmacies
- 69 percent increase in DAA funding in 2015-16
- Direct remuneration for NDSS
- Chemo funded outside the 6CPA envelope









Thank You Questions?

